ETCK yields 666666.67% · JNJ yields 2.13%● Live data
📍 ETCK pulled ahead of the other in Year 1
Combined, ETCK + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ETCK + JNJ for your $10,000?
EnerTeck Corporation, through its subsidiary, EnerTeck Chemical Corp., manufactures, markets, and sells fuel borne catalytic engine treatment products for diesel engines in the United States and internationally. The company offers EnerBurn that functions as an engine treatment application by removing carbon deposits from the combustion surfaces of the engine and reducing further carbon deposit buildup to fleet and vessel operators. It also provides volumetric proportioning injection equipment, which is used to deliver proper dosage ratios of EnerBurn to the diesel fuel. The company's products are primarily used in on-road vehicles, locomotives, and diesel marine engines. Its principal target markets comprise trucking, heavy construction, maritime shipping, railroad, and mining industries, as well as federal, state, and international government applications. The company was formerly known as Gold Bond Resources, Inc. and changed its name to EnerTeck Corporation in November 2003. EnerTeck Corporation was incorporated in 1935 and is based in Stafford, Texas.
Full ETCK Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.